HedgePath Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (19)

View All

Latest Posts

About This Stock More About This Stock
HedgePath Granted Type C Meeting With FDA
Article By: Jason Napodano
Thursday, June 1, 2017 10:46 AM EDT
edgePath Pharmaceuticals, Inc. (HPPI) announced the company has been granted a Type C meeting with the U.S. FDA to discuss the interim results from the company's Phase 2b clinical study of SUBA-Cap.
In this article: HPPI
Read
Why I'm Long Shares Of HedgePath Pharma
Article By: Jason Napodano
Wednesday, March 22, 2017 12:44 PM EDT
HedgePath remains an attractive story for small-cap biotech investors. The company is likely to report positive top-line Phase 2b results during the first half of 2017.
In this article: HPPI
Read
Phase 2b Data Continues To Impress From HedgePath Pharma
Article By: Jason Napodano
Friday, October 21, 2016 4:18 AM EDT
HedgePath Pharma reported interim results from its ongoing Phase 2b data in patients with Basal Cell Carcinoma Nevus Syndrome.
In this article: HPPI Also: NVS, RHHBY
Read
All Posts

Latest Tweets for $HPPI

No tweets yet!

PARTNER HEADLINES